Overview
Nicotine pouches have rapidly become a focal point of Big Tobacco's attempts to build new growth avenues beyond traditional cigarettes. These small, tobacco-free sachets - placed under the lip and delivering nicotine directly - are drawing attention for their brisk adoption in certain markets, higher per-unit profitability versus cigarettes and, to date, relatively lighter regulation than some smoking alternatives.
Market momentum and company positions
Two major industry players, Philip Morris International and British American Tobacco, have positioned pouch brands at the center of their product portfolios in regions where oral nicotine products already have traction, notably Scandinavia and the United States. British American Tobacco has reported rising demand for pouches in markets such as Britain and Poland. Across Asia, the Middle East and Africa, BAT said volumes rose 27.5% to about 700 million pouches in the first half of 2026 - a meaningful expansion but still small compared with the more than 3 billion pouches sold in its U.S. and European businesses.
Executives see pouches as an efficient format. BAT Chief Executive Tadeu Marroco said in an interview: "I do believe that this is an engine of growth ... that has the potential to replace cigarettes in the long run," adding that pouches can be cheaper and easier to use than many smoking alternatives.
Growth projections and unit economics
Industry forecasts cited by BAT anticipate significant expansion: pouch revenues are projected to climb from £4 billion in 2025 to £11 billion by 2030, overtaking vapes in revenue terms. The company expects about 47 million pouch users by 2030, which it notes would be just over half the number of vape users.
That unit economics story is a core reason investors are watching closely. Philip Morris reported that its U.S. pouch business generated eight times the gross profit per thousand units of its international cigarette business in 2024. By comparison, its IQOS heated tobacco device produced 2.4 times the gross profit per thousand units. Such spreads help explain why analysts say valuations for tobacco companies are increasingly tied to pouch performance.
Jefferies analyst Andrei Andon-Ionita has observed that pouch performance is becoming a larger component of tobacco company valuations. Investors and some asset managers see pouches as reopening opportunities for nicotine consumption since they do not produce smoke or vapour and can be used in locations where other products are restricted, according to Anthony Sedgwick, co-founder of BAT investor Abax Investments.
Analysts also point out market structure differences. Quilter Cheviot analyst Chris Beckett noted that BAT and Philip Morris dominate pouch sales, in contrast with vaping where Chinese manufacturers have outsized influence.
Regulation and public health considerations
Regulatory and public health bodies have taken a cautious, sometimes mixed view. The U.S. Food and Drug Administration states that smokers who switch completely to alternatives such as pouches, vapes and heated tobacco products may reduce their health risks. Observational experience spanning decades in Sweden and Norway suggests oral nicotine products carry substantially lower risks than smoking, though experts emphasize pouches are not risk-free.
At the same time, authorities and public health groups are increasingly alarmed about youth uptake and promotional practices. Some companies have used channels for pouch promotion that they generally avoid for other nicotine products, including sports and music sponsorships and free samples. The World Health Organization has said "pouch uptake is being driven by aggressive marketing and high nicotine strengths that appeal to new users," and has called for tighter controls. The WHO also noted in May that 160 countries still lacked specific regulations governing pouches, leaving the category less regulated than vapes or heated tobacco products in many markets.
Responses are already visible. France has implemented an outright ban on pouches, Finland has introduced measures including plain packaging, and regulatory authorities in Britain and the European Union are moving toward tighter rules. Both BAT and Philip Morris say they support appropriate regulation. Analysts caution, however, that more restrictive rules could slow the pace of expansion.
Can pouches spread beyond current strongholds?
A central question for investors and company strategists is whether pouches can gain the same level of acceptance in markets without an established oral-nicotine culture. Analysts point to cultural and behavioral differences: consumers in many countries may be more accustomed to inhaling nicotine than consuming it orally, and the absence of an oral nicotine tradition outside a few markets is considered a major adoption barrier.
At present cigarettes remain the industry's profit backbone. Philip Morris reported that oral nicotine products account for just 2.6% of its total volumes. When an unexpected rise in cigarette sales helped Philip Morris beat second-quarter expectations, Bernstein analysts cautioned that investor focus on the company's pouch brand Zyn had risked obscuring the continued significance of its traditional business. Both BAT and Philip Morris argue that adult smokers are not homogeneous in their preferences. A Philip Morris spokesperson said: "Adult smokers are not a homogenous group of people with the same preferences, rituals or taste," and that having a diverse portfolio of alternatives is key.
What this means for markets and investors
The combination of fast unit growth, attractive margins and the relatively limited number of major players in the pouch market supports the view that pouches could be a material contributor to industry profit pools over the coming years. Yet two principal constraints could limit that outcome: the challenge of persuading smokers in markets without oral-nicotine traditions to switch, and the potential for tightened regulation in response to youth uptake and marketing tactics.
Key points
- Pouches are expanding quickly and deliver higher gross profit per thousand units than international cigarettes, according to company disclosures.
- BAT projects pouch revenue to rise from £4 billion in 2025 to £11 billion by 2030 and expects about 47 million users by that time.
- The category faces regulatory scrutiny and adoption challenges in markets without an oral-nicotine tradition; major companies say a diverse product portfolio is essential.
Risks and uncertainties
- Regulatory risk - Tightening rules in jurisdictions such as France, Finland, Britain and the EU, and WHO concerns about marketing and youth uptake, could slow growth; this impacts consumer goods and tobacco sector revenues.
- Adoption risk - The lack of an oral-nicotine culture outside certain markets could limit pouch penetration, affecting long-term revenue forecasts and valuation assumptions for tobacco companies.